We discuss concerns regarding the necessity of repeated radioactive iodine treatments described by Kuhlen et al. (2025) in a pediatric thyroid carcinoma patient who developed fatal pulmonary fibrosis. Clarification on criteria for treatment continuation is needed, especially considering advances in dosimetry and imaging that may significantly influence current clinical decisions.
Objective: Pathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations. 68 Ga-PSMA-11 PET/CT is promising for characterizing tumor biology. The 5-point PRIMARY score, which considers uptake, focality, and location, has limited data on predicting occult high-grade cancer in GG1 biopsy patients. This study assessed the score’s accuracy in predicting upgrading in GG1 prostate cancer patients with PSA < 20 ng/mL undergoing radical prostatectomy. Materials and methods: This retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA < 20 ng/mL, and 68 Ga-PSMA-11 PET/CT performed within 2 months before radical prostatectomy. PRIMARY scores [1–5] were assigned by two blinded nuclear medicine physicians; scores ≥ 4 were considered high-risk. Pathological upgrading was defined as ISUP GG ≥ 2 on prostatectomy specimens. Diagnostic performance was assessed using ROC analysis, and univariate and multivariate logistic regression models were constructed to determine independent predictors of upgrading. Results: Pathological upgrading occurred in 45/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores ≤ 3, 81.3% for score 4, and 100% for score 5 ( p < 0.001). A PRIMARY score ≥ 4 demonstrated excellent diagnostic performance (AUC = 0.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC = 0.944) and PI-RADS ≥ 4 (AUC = 0.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28; p = 0.002). Conclusion: “The 68 Ga-PSMA-11 PET/CT PRIMARY score was strongly associated with pathological upgrading in this surgically treated cohort of biopsy-confirmed ISUP GG1 patients with PSA < 20 ng/mL undergoing radical prostatectomy. Incorporating PSMA-based intraprostatic pattern analysis could improve the accuracy of preoperative grading, potentially supporting consideration of surgical management rather than definitive radiotherapy when determining the optimal treatment strategy. Prospective multicenter validation is warranted before broader clinical implementation.
20 March 2026 in Journal of Clinical and Analytical Medicine
Aim The FIB-4 index is a widely used noninvasive marker of hepatic fibrosis and has prognostic value in hepatocellular carcinoma (HCC). However, its association with tumor differentiation remains unclear. This study aimed to investigate the relationship between the fibrosis-4 (FIB-4) index and histological differentiation of HCC using 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters. Methods This retrospective, single-center study included 110 patients with newly diagnosed, histologically confirmed HCC who underwent 18F-FDG PET/CT between 2017 and 2024. Patients with moderately differentiated or unclassified tumors, prior liver-directed therapies, recurrent HCC, or other malignancies were excluded. Tumors were categorized as well-differentiated or poorly-differentiated. PET/CT-derived metabolic parameters were analyzed. The FIB-4 index was calculated at the time of imaging. Group comparisons, correlation analyses, and receiver operating characteristic (ROC) curve analyses were performed to evaluate associations among FIB-4, metabolic parameters, and tumor differentiation. Results The median FIB-4 index did not differ significantly between well- and poorly differentiated HCC groups (4.2 vs. 4.5, p = 0.765). No significant correlation was observed between the FIB-4 index and PET metabolic parameters (all p > 0.05). In contrast, poorly-differentiated HCCs showed significantly higher metabolic activity, with markedly elevated SUVmax, SUVmean, SUVpeak, tumor-to-liver and tumor-to-blood ratios (all p < 0.001). ROC analysis showed that SUVmax had the highest diagnostic performance for predicting poor differentiation (AUC = 0.981), whereas the FIB-4 index had poor discriminative ability (AUC = 0.517). Conclusion The FIB-4 index does not reflect histological differentiation in HCC and has limited utility for tumor grading. 18F-FDG PET/CT metabolic parameters provide superior discrimination of tumor differentiation, although overlap between grades underscores the need for a multimodal diagnostic approach.
Incidental renal abnormalities may be encountered during oncologic 18F-FDG PET/CT interpretation, but their prevalence and imaging spectrum remain insuffic
Standardized interpretation of [18F]FDG PET/CT in multiple myeloma remains challenging because reproducibility varies across visual parameters. The Italian Myeloma criteria for PET Use (IMPeTUs) provide a structured framework, but evidence on intra-observer and inter-observer agreement remains limited, particularly across institutions. We prospectively registered patients with histopathologically confirmed multiple myeloma undergoing [18F]FDG PET/CT between March and September 2025. Fifty patients were included according to a prespecified target sample size. After anonymization, three independent nuclear medicine physicians from different institutions evaluated all examinations twice over 10 weeks using a blinded repeated-reader design with software-randomized weekly case allocation and presentation order. Intra-observer agreement was assessed using Cohen’s kappa, inter-observer agreement using Krippendorff’s alpha and pairwise kappa, and differences between reading rounds using permutation-based methods. An exploratory whole-patient binary metabolic status analysis using a Deauville score 4 threshold was also performed. Inter-observer agreement was highest for Lytic Lesion Group (α = 0.683 and 0.784) and Hottest Bone Focal Lesion Deauville score (α = 0.657 and 0.641). Bone Marrow Deauville score showed α values of 0.560 and 0.626, whereas Focal Lesion Group yielded 0.538 and 0.491. Fracture and Extramedullary Disease Presence showed lower agreement (α = 0.280 and 0.235; α = 0.412 and 0.262, respectively). Intra-observer agreement was highest for Hottest Bone Focal Lesion Deauville score (κ = 0.846–0.891), Lytic Lesion Group (κ = 0.759–0.905), and Focal Lesion Group (κ = 0.679–0.855). For exploratory patient-level binary metabolic status, inter-observer agreement was moderate to good (α = 0.611 and 0.542), while intra-observer agreement was good to excellent (κ = 0.626–0.822). No parameter showed a statistically significant change between reading rounds. IMPeTUs supports structured [18F]FDG PET/CT interpretation in multiple myeloma, but reproducibility differs across components, underscoring the need for clearer operational definitions and targeted training for less reproducible parameters.